Print Friendly, PDF & Email

NCT/Study#

NA /

MGD019-01

A Phase 1, First-in-Human, Open- Label, Dose Escalation and Cohort Expansion Study of MGD019, a Bispecific DART® Protein Binding PD-1 and CTLA-4 in Patients with Unresectable or Metastatic Neoplasms? (the ?Study?).

DISEASE GROUP:
Phase 1 Clinical Trials
current phase:
Phase I
STUDY STATUS:
Active
Location:
Hackensack, NJ
For More information: